Human IL-15, premium grade 130-095-765 from Miltenyi Biotec

(1) Targeting PD-1+ T cells with chimeric antigen receptors to reduce the HIV reservoirSci AdvApril 24, 2026Laura Ermellino, Riddhima Banga, Spiros Georgakis, Nicole P. Kadzioch, Francesco Procopio, Ana Alcaraz-Serna, Oscar Alfageme-Abello, Raphaël Porret, Rebecca Cecchin, Michail Orfanakis, et al.catalog no. 130-095-362), rhIL-15 (5 ng/ml; Miltenyi Biotec, Bergisch-Gladbach, Germany, catalog no. 130-095-764), and IL-2 (30 IU/ml). Primary T cells were cultured at a confluency of 1 to 2 × 106 cells/ml at 37°C

(2) Identification of immunogenic neoantigens from intron retention in colorectal cancerScientific ReportsMarch 9, 2026Thamizhanban Manoharan, Brandon Bing Rui Kee, Cyrus Zai Ming Cheng, Malcolm Kaiheng Choy, Bei En Siew, Wai-Kit Cheong, Kai-yin Lee, Ian Jse-Wei Tan, Bettina Lieske, Choon Kong Yap, et al.IL-21 (Miltenyi #130-095-768), 40 ng/ml IL-7 (Miltenyi #130-095-361), and 40 ng/ml IL-15 (Miltenyi #130-095-762)) in a 48-well plate. After three days of coculture, on day four, the expansion media (RPMI 1640 with

(3) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerCancer CellMarch 5, 2026Marco Campisi, Tatsuya Osaki, Ian Dryg, Carla Stornante, Jacqueline Wolff, Jason Weirather, Nicholas Weaver, Mubin Tarannum, Ian Gillanders, Alan Bers, et al.2503049) with the cytokines IL-12 (10 ng/mL, R&D, Cat# 219-IL/CF), IL-15 (50 ng/mL, Miltenyi Biotec, Cat# 130-095-762), and IL-18 (50 ng/mL, R&D, Cat# 9124-IL/CF). After activation, the cells were transduced with DLL3-CAR

(4) Multiplexed high-content imaging uncovers morphological diversity of lymphocyte activation and dysfunctionbioRxivFebruary 14, 2026Julie C. Matte, Olivier B. Bakker, Madeline A. Ohl, Francesco Cisternino, Andrea J. Manrique-Rincón, Anke Husmann, Florence Lichou, Tong Li, Kwasi Kwakwa, Anneliese O. Speak, et al.TransAct (1:100) and IL-2 (100 U/mL). After the third stimulation, IL-15 (10 ng/mL, Miltenyi Biotec, #130-095-762) was added. Comparisons were made with CD8 T cells activated for 72h and then expanded for the duration

(5) CAR-adapted PIK3CD base editing enhances T cell anti-tumor potencyNature CancerJanuary 6, 2026Philip Bucher, Nadine Brückner, Jule Kortendieck, Melanie Grimm, Jan T. Schleicher, Karlotta Bartels, Steffen Hardy, Martina Rausch, Hannah Wurzer, Meike Thiemann, et al.(Thermo Fisher, 11161D) in the presence of 5 ng ml−1 IL-7 and IL-15 (Miltenyi Biotec, 130-095-363 and 130-095-765). Cells were cultured at 1 × 106 cells per ml in X-Vivo15 (Lonza, BEBP02-061Q), which was supplemented

(6) "Live" cell shipment-a forward-looking transport option for cryo-sensitive cell-based therapiesFront Bioeng BiotechnolDecember 9, 2025Lutz Roßbach, Thea Eichenberg, Nicole Pietzsch, Paul Franz, Stephan Fricke, Robin Sieg, Anna Dünkel, Kathrin Sabine AdlkoferBio&SELL (Cat. No.: HUAB.SE.010), and IL-2 (500 U/mL; Cat. No.: 130-097-142) and IL-15 (140 U/mL; Cat No.: 130-095-764) from Miltenyi Biotec. The NK cells were expanded and activated without feeder cells. The incubation

(7) Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma modelFrontiers in ImmunologyNovember 27, 2025Lena Andersch, Laura Grunewald, Maria Stecklum, Filippos Klironomos, Kerstin Haase, Viola Hollek, Tobias Lam, Beate Anahita Jung, Anika Winkler, Silke Schwiebert, et al.Cells were expanded in T cell medium (changed every 2–3 days) supplemented with 0.5 ng/ml IL15 (cat# 130-095-765, Miltenyi Biotec) and 5 ng/ml IL7 (cat# 130-095-362, Miltenyi Biotec). Knockout efficiency was analyzed

(8) Defined metabolic states shape T cell fate and function across culture conditionsFrontiers in ImmunologyNovember 6, 2025Kayla Sylvester, Natasha Karassina, Anthony C. Lauer, Gediminas Vidugiris, Jolanta Vidugiriene#10971) and supplemented with IL-7 and IL-15 each at 2.5 ng/mL (Miltenyi Biotec, Cat. #130-095–361 and #130-095-764). On Day 3, metabolic activity was evaluated using bioluminescent assays (see Bioluminescent Metabolite

(9) Eradicating Drug-tolerant Persister Cells in EGFR- Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular TherapyCancer DiscoveryNovember 3, 2025Simon Baldacci, Elliott J. Brea, Francesco Facchinetti, Zhaorong Li, Kenneth Ngo, Soumya Malhotra, Matthew A. Booker, Michael Yevgeniy Tolstorukov, Sachiv Chakravarti, Conor Hinchey, et al.Miltenyi Biotec #130-097-743), IL7 (3 ng/mL; Miltenyi Biotec #130-095- 361), and IL15 (10 ng/mL; Miltenyi Biotec #130-095-762), in RPMI1640 supplemented 10% FBS, and their transduction efficiency was determined by FACS 3 days

(10) Unveiling the influence of CAR-negative T-cells: enhancing efficacy and ensuring safety in CAR-T therapiesJ Transl MedAugust 19, 2025Belén Sierro-Martínez, Beatriz Guijarro-Albaladejo, Ricardo Fernández-Cisnal, Alfonso Rodríguez-Gil, Paola Hernández-Díaz, María de la Rosa-Garrido, Inmaculada Carrasco-Brocal, Maribel Lara-Chica, Virginia Escamilla-Gómez, Raquel Muñoz-García, et al.IU/mL IL-2 (Miltenyi Biotec, 130-097-743) or 10 ng/mL IL-7 and IL-15 (Miltenyi Biotec, 130-095-367, 130–095-765) in RPMI (Gibco, 61870036) with 1% Pennicillin/Streptomycin (Gibco, 15140-122) and 10% fetal bovine

(11) Dual targeting of CD155/TIGIT and PD-L1/PD-1 Immune Checkpoints Potentiates NK Cell-mediated Cytotoxicity in MedulloblastomaNeuro-Oncology AdvancesJuly 24, 2025Matthijs Monnikhof, Michael Y Schakelaar, Chris Meulenbroeks, Matthias Quist, Alicia Perzolli, Aimee Selten, Celeste J M Koster, Daniëlle S C Maassen, Alba Montoro Canelo, Maureen Fredriks, et al.with 1000 IU/mL IL-2 (Miltenyi Biotec, cat. #130-097-742) and 50 ng/mL IL-15 (Miltenyi Biotec, cat. #130-095-765) for 2 hours at 37 °C. NK Cell—Medulloblastoma Cell Co-Culture Daoy and MB cell lines were trypsinized

(12) Highly adaptable deep-learning platform for automated detection and analysis of vesicle exocytosisNature communicationsJuly 12, 2025Chouaib AA, Chang HF, Khamis OM, Alawar N, Echeverry S, Demeersseman L, Elizarova S, Daniel JA, Tian Q, Lipp P, et al.(rIL-2; 100 IU/ml, Miltenyi Biotec Cat# 130-097-748), and human rIL-15 (50 ng/ml, Miltenyi Biotec, Cat# 130-095-766). Blood samples were collected and processed following standard ethical procedures after obtaining written

(13) CSPG4.CAR-T Cells Modulate Extracellular Matrix Remodeling in DMD CardiomyopathyInternational journal of molecular sciencesJuly 9, 2025Ceraolo MG, Milan M, Fratini N, Viganò R, Bousselmi S, Soluri A, Pesce E, Mauri PL, Ciuffreda G, Landoni E, et al.presence of 100 U/mL IL-2, 10ng/mL of IL-7 (Miltenyi, 130-095-362), and 4 ng/mL of IL15 (Miltenyi, 130-095-764). Then T cells were transferred to a tissue-culture-treated plate and then expanded in complete medium

(14) Cutting Edge: Cooperative interferon regulatory factor network shapes the NK-cell antiviral responseThe Journal of ImmunologyJune 1, 2025Endi K. Santosa, Jennifer M. Zhang, John C. Sauter, Mark Owyong, Joseph C. Sunpyruvate, 1× BME, 1× MEM-NAA, 1× Penicillin/Streptomycin, and human IL-15 (50ng/ml; Miltenyi Biotech, 130–095-766). For intracellular staining, cells were fixed in eBiosicence Intracellular Fix/Perm buffer and stained

(15) Nucleofection-based screening of chimeric antigen receptor candidates in human natural killer cellsFront ImmunolApril 3, 2025Chelsia Qiuxia Wang, Leonard Leong, Lei Yang, Shengli Xu, Kong-Peng Lam, Andre Boon-Hwa Choo, Andy Hee-Meng Tanrecombinant human IL-7 (Miltenyi Biotec #130-095-362), 10 U/ml recombinant human IL-15 (Miltenyi Biotec #130-095-764) and 0.04 U/ml recombinant human IL-21 (Miltenyi Biotec #130-095-769) for 3 days. Electroporation was

(16) Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathwayCell Rep MedFebruary 18, 2025Elham Adabi, Filippos T. Charitidis, Frederic B. Thalheimer, Mar Guaza-Lasheras, Colin Clarke, Christian J. Buchholzrecombinant proteins" ,, Interleukin-7,Miltenyi Biotec,Cat#130-095-361 Interleukin-15,Miltenyi Biotec,Cat#130-095-765 Benzonase,Sigma,Cat#E1014 dasatinib,Selleck Chemicals,Cat#S1021 deucravacitinib,medchemexpress,Cat#HY-117287 ulixertinib,medchemexpress,Cat#HY-15816 ravoxertinib,medchemexpress,Cat#HY-15947 selumetinib,medchemexpress,Cat#HY-50706 VX-11e,medchemexpress,Cat#HY-14178 Propidium

(17) ThymoSpheres culture: A model to study human polyclonal unconventional T cellsEuropean Journal of ImmunologyDecember 1, 2024Lore Billiet, Hanne Jansen, Melissa Pille, Lena Boehme, Guillem Sanchez Sanchez, Laurenz De Cock, Glenn Goetgeluk, Eva Pascal, Stijn De Munter, Lucas Deseins, et al.100 µL cIMDM supplemented with IL‐7 (10 ng/mL; Miltenyi, 130‐095‐362) or IL‐15 (10 ng/mL; Miltenyi, 130‐095‐765). After 5 days, the cells were harvested, as described above, and analyzed via flow cytometry. Single‐cell

(18) Generation, expansion, gene delivery, and single-cell profiling in rhesus macaque plasma B cellsCell Rep MethodsOctober 21, 2024Yu-Hong Cheng R, Helmers AE, Kreuser S, Dahl N, Honaker Y, Lopez C, Rawlings DJ, James RG.ACF,StemCell,10974 Multimeric CD40L,Adaptogen,AG-40B-0010 IL-2,PeproTech,AF-200-02 IL-10,PeproTech,200–10 IL-15,Miltenyi,130-095-765 IL-21,PeproTech,200–21 IL-6,PeproTech,200–06 IFN alpha 2B,Proteintech,HZ-1072 AF350 amine reactive

(19) T-cell specific in vivo gene delivery with DART-AAVs targeted to CD8Molecular TherapyOctober 2, 2024Muhammed Burak Demircan, Luca J. Zinser, Alexander Michels, Mar Guaza-Lasheras, Fabian John, Johanna M. Gorol, Samuel A. Theuerkauf, Dorothee M. Günther, Dirk Grimm, Florian R. Greten, et al.supplemented with IL-7 (25 U/mL, Miltenyi Biotec, 130-095-361) and IL-15 (50 U/mL, Miltenyi Biotec, 130-095-764). Three days after activation, medium was replaced with NutriT-medium containing IL-7 and IL-15. Murine

(20) Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trialNature CommunicationsAugust 11, 2024Szymon J. Szymura, Lin Wang, Tiantian Zhang, Soung-chul Cha, Joo Song, Zhenyuan Dong, Aaron Anderson, Elizabeth Oh, Vincent Lee, Zhe Wang, et al.grade), IL-7 at 25 ng/mL (Miltenyi Biotec, Cat# 130-095-361) and IL-15 at 25 ng/mL (Miltenyi Biotec, Cat# 130-095-762) to a concentration of 2 × 106 cells/mL. 125 µl of cell suspension were plated in V-bottom 96-well plates.

Be the First to Write a Review!

Human IL-15, premium grade from Miltenyi Biotec

Description

Miltenyi Biotec

Miltenyi Biotec

Citations (73)

Reviews

Human IL-15, premium grade from Miltenyi Biotec

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map